← Back to all trials
Active Not Recruiting
NCT04323774
Intervention For Adolescents and Young Adults (AYAs) With Cancer Risk Syndromes
Conditions: Cancer Risk Syndrome
Sex: All
Ages: 12 Years – 24 Years
Healthy volunteers: Yes
Phase: NA
Enrollment: 115
Sponsor: Dana-Farber Cancer Institute
Location: Emory University School of Medicine Atlanta Georgia
Summary
This research is being done because there is a need to improve cancer risk communication and decision-making among adolescents and young adults. In this study, the investigators are looking at whether using a chatbot and online portal for cancer risk information helps improve communication and decision-making.
* Over 70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the U.S. every year and up to 10% have genetic changes (or, mutations) that put them at a higher risk of developing new cancers during their lifetimes. These genetic mutations can result in cancer risk syndromes (such as, Lynch Syndrome or Li-Fraumeni Syndrome). Identifying cancer risk syndromes can allow for screening and early diagnosis of future cancers, which could ultimately save lives and offer more care choices for patients. As a result, genetic counseling and testing for cancer risk syndromes is being recommended more for Adolescents and Young Adults with new cancer diagnoses, regardless of family history.
* This research study to develop an intervention called AYA-RISE that aims to assist AYAs with cancer risk communication and decision-making around their caregivers.
Eligibility Criteria
Inclusion Criteria:
* Across all study aims, we will enroll AYA patients, family members/caregivers, and providers.
AIM 1, PART 1 - STAKEHOLDER INTERVIEWS
AYA Patients
1. Ages 12-24 years, inclusive
2. Diagnosed with a cancer risk syndrome
3. English-speaking and -reading
4. Receiving care at any of the study sites OR participating in the LiFraumeni Syndrome Association (LFSA) Youth Conference
5. Adequate cognitive function per NeuroQOL indicated by a score of 30 or greater
6. Not receiving active cancer therapy
Family caregivers-Inclusion Criteria
1. Parent/guardian, spouse/partner, or other family member who participates in the care of AYAs aged 12-24 with cancer risk syndromes
2. English-speaking and -reading
3. At any of the study sites
Providers Inclusion Criteria (Oncologists, nurses, genetic counselors, social workers, or psychologists)
1. English-speaking and reading
2. Caring for AYAs aged 12-24 with cancer risk syndromes at any of the study sites
AIM 1, PART 2 - INTERVENTION PILOT
AYA Patients
1. Ages 12-24 years, inclusive
2. Diagnosed with a cancer risk syndrome
3. English-speaking and -reading
4. Receiving care at Dana-Farber Cancer Institute
5. Adequate cognitive function per NeuroQOL, indicated by a score of 30 or greater
6. Not receiving active cancer therapy
7. Did not participate in a stakeholder interview
Eligibility notes:
* Family caregivers of participating 12-17y patients will be eligible to participate in the pilot
* 12-17y patients can participate without a family member if both the patient and family member agree.
* Patients 18-24y will have the option to participate with or without a family member.
AIM 2 - RANDOMIZED TRIAL
AYA Patients
1. Ages 12-24 years, inclusive
2. Diagnosed with a cancer risk syndrome
3. English-speaking and reading
4. Has a planned post-disclosure genetic counseling or follow-up visit at any of the study sites
5. Adequate cognitive function per NeuroQOL, indicated by a score of 30 or greater
6. Not receiving active cancer therapy
7. Did not participate in either part of Aim 1 (interview or pilot)
Family caregivers
1. Parent/guardian, spouse/partner, or other family member who participates in the care of AYAs aged 12-24 with cancer risk syndromes
2. English-speaking and -reading
3. At any of the study sites
4. Did not participate in either part of Aim 1 (interview or pilot)
AIM 3 - SEMI-STRUCTURED INTERVIEWS AYA Patients, Family Caregivers, Providers, and Site PIs
1. Participated in the intervention arm of Aim 2, or
2. Is a site principal investigator at one of the 4 participating study sites
Source: ClinicalTrials.gov (NCT04323774). StuddyBuddy aggregates publicly available trial information.